Atypical Depression

[1]  J. Stewart,et al.  Is duloxetine effective treatment for depression with atypical features? , 2008, International clinical psychopharmacology.

[2]  S. Roose.  Identifying and treating cognitive impairments in elderly patients. , 2007, The Journal of clinical psychiatry.

[3]  P. Masand,et al.  Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion , 2007, Expert review of neurotherapeutics.

[4]  A. Patkar,et al.  Selegiline transdermal system: Current awareness and promise , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[5]  M. Thase.  Recognition and diagnosis of atypical depression. , 2007, The Journal of clinical psychiatry.

[6]  M. Thase,et al.  Translating the evidence on atypical depression into clinical practice. , 2007, The Journal of clinical psychiatry.

[7]  M. Thase,et al.  Atypical depression: a valid subtype? , 2007, The Journal of clinical psychiatry.

[8]  J. Davidson,et al.  A history of the concept of atypical depression. , 2007, The Journal of clinical psychiatry.

[9]  M. Thase,et al.  A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. , 2007, The Journal of clinical psychiatry.

[10]  M. Fava,et al.  Resolution of Sleepiness and Fatigue in Major Depressive Disorder: A Comparison of Bupropion and the Selective Serotonin Reuptake Inhibitors , 2006, Biological Psychiatry.

[11]  J. Amsterdam,et al.  Selegiline Transdermal System in the Prevention of Relapse of Major Depressive Disorder: A 52-Week, Double-blind, Placebo-Substitution, Parallel-Group Clinical Trial , 2006, Journal of clinical psychopharmacology.

[12]  K. Rickels,et al.  Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. , 2006, The Journal of clinical psychiatry.

[13]  P. Masand,et al.  Transdermal Selegiline: The New Generation of Monoamine Oxidase Inhibitors , 2006, CNS Spectrums.

[14]  M. Fava,et al.  Modafinil Augmentation of SSRI Therapy in Patients with Major Depressive Disorder and Excessive Sleepiness and Fatigue: A 12-Week, Open-label, Extension Study , 2006, CNS Spectrums.

[15]  H. Möller,et al.  Treatment of depression with atypical features: A meta-analytic approach , 2006, Psychiatry Research.

[16]  D. Sack,et al.  A Double-Blind, Placebo-Controlled, Exploratory Trial of Chromium Picolinate in Atypical Depression: Effect on Carbohydrate Craving , 2005, Journal of psychiatric practice.

[17]  A. Rush,et al.  Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. , 2005, The Journal of clinical psychiatry.

[18]  A. Rush,et al.  Gender differences in depression: findings from the STAR*D study. , 2005, Journal of affective disorders.

[19]  H. Sackeim,et al.  An open trial of venlafaxine for the treatment of late‐life atypical depression , 2004, International journal of geriatric psychiatry.

[20]  A. Farmer,et al.  Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life. , 2004, European journal of endocrinology.

[21]  G. Kaprinis,et al.  The relationship of regional cerebral blood flow with subtypes of major depression , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[22]  R. Fieve,et al.  Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. , 2003, The Journal of clinical psychiatry.

[23]  G. Kaprinis,et al.  Pattern-reversed visual evoked potentials in subtypes of major depression , 2003, Psychiatry Research.

[24]  J. Lönnqvist,et al.  Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weather-associated changes in mood and behaviour , 2003, European Neuropsychopharmacology.

[25]  F. Benazzi.  Testing DSM-IV Definition of Atypical Depression , 2003, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[26]  J. Amsterdam.  A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. , 2003, The Journal of clinical psychiatry.

[27]  J. Davidson,et al.  Effectiveness of chromium in atypical depression: a placebo-controlled trial , 2003, Biological Psychiatry.

[28]  J. Amsterdam,et al.  Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. , 2002, The American journal of psychiatry.

[29]  K. Merikangas,et al.  Toward validation of atypical depression in the community: results of the Zurich cohort study. , 2002, Journal of affective disorders.

[30]  G. Parker,et al.  Atypical depression: a reappraisal. , 2002, The American journal of psychiatry.

[31]  H. Murck.  Die atypische Depression und verwandte Erkrankungen – Neurobiologische Grundlagen für ihre Behandlung mit Johanniskraut‐Extrakt* , 2002 .

[32]  F. Quitkin,et al.  Atypical depression: enhanced right hemispheric dominance for perceiving emotional chimeric faces. , 2002, Journal of abnormal psychology.

[33]  F. Quitkin.  Depression With Atypical Features: Diagnostic Validity, Prevalence, and Treatment. , 2002, Primary care companion to the Journal of clinical psychiatry.

[34]  F. Quitkin,et al.  Do Age of Onset and Course of Illness Predict Different Treatment Outcome among DSM IV Depressive Disorders with Atypical Features? , 2002, Neuropsychopharmacology.

[35]  P. Sullivan,et al.  Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. , 2001, The Australian and New Zealand journal of psychiatry.

[36]  M. Schaffer,et al.  Reducing Relapse in Depressed Outpatients with Atypical Features: A Pilot Study , 2000, Psychotherapy and Psychosomatics.

[37]  D. Klein,et al.  A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. , 2000, The American journal of psychiatry.

[38]  K. Behnke,et al.  A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression , 1999, Journal of psychopharmacology.

[39]  M. Schaffer,et al.  Treatment of Atypical Depression With Cognitive Therapy or Phenelzine A Double-blind, Placebo-Controlled Trial , 1999 .

[40]  P. Sullivan,et al.  Latent class analysis of lifetime depressive symptoms in the national comorbidity survey. , 1998, The American journal of psychiatry.

[41]  H. Akiskal,et al.  The high prevalence of "soft" bipolar (II) features in atypical depression. , 1998, Comprehensive psychiatry.

[42]  D. Orth,et al.  Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression , 1997, Biological Psychiatry.

[43]  S. Kennedy,et al.  Reversed neurovegetative symptoms of depression: a community study of Ontario. , 1997, The American journal of psychiatry.

[44]  M. Fava,et al.  Social phobia, avoidant personality disorder and atypical depression: co-occurrence and clinical implications , 1997, Psychological Medicine.

[45]  R. Lam,et al.  Atypical depressive symptoms and clusters in unipolar and bipolar depression , 1996, Acta psychiatrica Scandinavica.

[46]  M. Birkett,et al.  Fluoxetine versus phenelzine in atypical depression , 1996, Biological Psychiatry.

[47]  R. Kessler,et al.  The identification and validation of distinct depressive syndromes in a population-based sample of female twins. , 1996, Archives of general psychiatry.

[48]  G. Asnis,et al.  Biological and clinical validation of atypical depression , 1996, Psychiatry Research.

[49]  Y. Lecrubier,et al.  Moclobemide versus clomipramine in nonmelancholic, nonpsychotic major depression , 1995, Acta psychiatrica Scandinavica.

[50]  J. Lonnqvist,et al.  Moclobemide and fluoxetine in atypical depression: a double-blind trial. , 1994, Journal of affective disorders.

[51]  M. Weissman,et al.  The validity of major depression with atypical features based on a community study. , 1992, Journal of affective disorders.

[52]  J. Stewart,et al.  A pilot sequential study of cognitive therapy and pharmacotherapy of atypical depression. , 1992, The Journal of clinical psychiatry.

[53]  E. Christensen,et al.  Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression , 1991, Acta psychiatrica Scandinavica.

[54]  D. Klein,et al.  Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design. , 1991 .

[55]  D. Klein,et al.  Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication. , 1990, Archives of general psychiatry.

[56]  G. Franck,et al.  Moclobemide versus clomipramine in the treatment of depression: a double‐blind multicentre study in Belgium , 1990, Acta psychiatrica Scandinavica. Supplementum.

[57]  D. Klein,et al.  Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression. , 1989, Archives of general psychiatry.

[58]  P. Goodnick,et al.  Bupropion and Fluoxetine in Depressive Subtypes , 1989 .

[59]  B. Davies,et al.  A sequential double-blind controlled study of moclobemide and diazepam in patients with atypical depression. , 1989, Journal of affective disorders.

[60]  D. Klein,et al.  Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. , 1988, The American journal of psychiatry.

[61]  J. Davidson,et al.  An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. , 1988, Archives of general psychiatry.

[62]  D. Klein,et al.  Antidepressant specificity in atypical depression. , 1988, Archives of general psychiatry.

[63]  M. Liebowitz,et al.  Biochemical effects of l-deprenyl in atypical depressives , 1985, Biological Psychiatry.

[64]  P. L. Mikkelsen,et al.  Moclobemide and clomipramine in the treatment of depression , 1984, Acta psychiatrica Scandinavica.

[65]  M. Liebowitz,et al.  l-Deprenyl in atypical depressives. , 1984, Archives of general psychiatry.

[66]  D. Klein,et al.  Phenelzine v imipramine in atypical depression. A preliminary report. , 1984, Archives of general psychiatry.

[67]  F. Quitkin,et al.  Monoamine oxidase inhibitors. A review of antidepressant effectiveness. , 1979, Archives of general psychiatry.

[68]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[69]  K. Lamborn,et al.  The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive -anxiety states. A controlled clinical trial. , 1973, Archives of general psychiatry.

[70]  P. Dally,et al.  Effects of Iproniazid in Depressive Syndromes , 1959, British medical journal.

[71]  P. Masand,et al.  An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features. , 2008, Primary care companion to the Journal of clinical psychiatry.

[72]  M. Posternak,et al.  Partial validation of the atypical features subtype of major depressive disorder. , 2002, Archives of general psychiatry.

[73]  M. Fava,et al.  Course and treatment of atypical depression. , 1998, The Journal of clinical psychiatry.

[74]  D. Rye,et al.  Reversal of atypical depression, sleepiness, and REM‐sleep propensity in narcolepsy with bupropion , 1998, Depression and anxiety.

[75]  J. Stewart,et al.  Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. , 1997, The American journal of psychiatry.

[76]  W. Sanderson,et al.  Atypical depression: clinical aspects and noradrenergic function. , 1995, The American journal of psychiatry.

[77]  S. Zisook,et al.  Atypical depression in an outpatient psychiatric population , 1993 .

[78]  D. Klein,et al.  A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. , 1993, The American journal of psychiatry.

[79]  P. Stratta,et al.  A Double‐blind Parallel Study Comparing Fluoxetine with Imipramine in the Treatment of Atypical Depression , 1991, International clinical psychopharmacology.

[80]  B. Davies,et al.  Treatment of atypical depression with moclobemide: a sequential double controlled study. , 1989, International journal of clinical pharmacology research.

[81]  J. Stewart,et al.  A placebo-controlled trial of L-deprenyl in atypical depression. , 1989, Psychopharmacology bulletin.

[82]  J. Rabkin,et al.  Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. , 1989, Psychopharmacology bulletin.

[83]  F. Reimherr,et al.  Characteristics of responders to fluoxetine. , 1984, Psychopharmacology bulletin.

[84]  W. Sargant.  Some Newer Drugs in the Treatment of Depression and Their Relation to Other Somatic Treatments , 1960 .